Cencora, Inc. (COR) EV/Sales Ratio: 0.20x
Is Cencora, Inc.’s EV/Sales ratio high or low?
Cencora, Inc.'s EV/Sales ratio of 0.20x is 16% above its 5-year average of 0.17x, around the middle of its 5-year range (0.12x–0.25x).
As of Saturday, June 13, 2026. 6.60% below its 12-month average of 0.21x.
COR EV/Sales Ratio Chart
COR Average EV/Sales Ratio Chart
COR Current vs Average EV/Sales Ratio Chart
COR EV/Sales Ratio Metrics
EV/SALES RATIO
0.20x
EV/SALES RATIO AVG TTM
0.21x
EV/SALES RATIO AVG 3Y
0.19x
EV/SALES RATIO AVG 5Y
0.17x
EV/SALES RATIO AVG 10Y
0.15x
EV/SALES RATIO AVG 15Y
0.15x
EV/SALES RATIO AVG 20Y
0.15x
CURRENT VS TTM AVG
-6.60%
CURRENT VS 3Y AVG
+6.14%
CURRENT VS 5Y AVG
+15.63%
CURRENT VS 10Y AVG
+33.44%
CURRENT VS 15Y AVG
+30.76%
CURRENT VS 20Y AVG
+37.76%
COR Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $54.80B | 0.20x | 0.21x | 0.19x | 0.17x |
| Becton, Dickinson and Company (BDX) | $52.98B | 2.69x | 2.87x | 3.33x | 3.47x |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.06B | 4.40x | 5.03x | 6.56x | 6.20x |
| Humana Inc. (HUM) | $45.53B | 0.40x | 0.30x | 0.40x | 0.54x |
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 10.37x | 12.33x | 11.50x | 12.37x |
| Agilent Technologies, Inc. (A) | $36.67B | 5.31x | 5.55x | 5.75x | 6.20x |
| Zoetis Inc. (ZTS) | $33.36B | 4.30x | 6.69x | 8.77x | 9.89x |
| Centene Corporation (CNC) | $32.19B | 0.14x | 0.11x | 0.20x | 0.29x |
| Medline Inc. (MDLN) | $30.96B | 1.39x | 1.60x | 1.60x | 1.60x |
| Cigna Corporation (CI) | $78.83B | 0.37x | 0.38x | 0.50x | 0.55x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Cencora, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Cencora, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Cencora, Inc. (COR)?
- The EV/Sales ratio for COR stock is 0.20x.
- Is Cencora, Inc.'s EV/Sales ratio high or low?
- Cencora, Inc.'s EV/Sales ratio of 0.20x is 16% above its 5-year average of 0.17x, around the middle of its 5-year range (0.12x–0.25x).
- What is the TTM average EV/Sales ratio for Cencora, Inc. (COR)?
- The TTM average EV/Sales ratio for COR stock is 0.21x.
- What is the 3Y average EV/Sales ratio for Cencora, Inc. (COR)?
- The 3Y average EV/Sales ratio for COR stock is 0.19x.
- What is the 5Y average EV/Sales ratio for Cencora, Inc. (COR)?
- The 5Y average EV/Sales ratio for COR stock is 0.17x.
- What is the 10Y average EV/Sales ratio for Cencora, Inc. (COR)?
- The 10Y average EV/Sales ratio for COR stock is 0.15x.
- What is the 15Y average EV/Sales ratio for Cencora, Inc. (COR)?
- The 15Y average EV/Sales ratio for COR stock is 0.15x.
- What is the 20Y average EV/Sales ratio for Cencora, Inc. (COR)?
- The 20Y average EV/Sales ratio for COR stock is 0.15x.
Cencora, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-12 | 0.20x |
| 2026-06-11 | 0.20x |
| 2026-06-10 | 0.20x |
| 2026-06-09 | 0.20x |
| 2026-06-08 | 0.19x |
| 2026-06-05 | 0.19x |
| 2026-06-04 | 0.19x |
| 2026-06-03 | 0.19x |
| 2026-06-02 | 0.19x |
| 2026-06-01 | 0.19x |
| 2026-05-29 | 0.19x |
| 2026-05-28 | 0.19x |
| 2026-05-27 | 0.19x |
| 2026-05-26 | 0.19x |
| 2026-05-22 | 0.19x |
| 2026-05-21 | 0.19x |
| 2026-05-20 | 0.19x |
| 2026-05-19 | 0.19x |
| 2026-05-18 | 0.19x |
| 2026-05-15 | 0.18x |
| 2026-05-14 | 0.19x |
| 2026-05-13 | 0.18x |
| 2026-05-12 | 0.19x |
| 2026-05-11 | 0.19x |
| 2026-05-08 | 0.19x |
| 2026-05-07 | 0.18x |
| 2026-05-06 | 0.18x |
| 2026-05-05 | 0.20x |
| 2026-05-04 | 0.20x |
| 2026-05-01 | 0.20x |
| 2026-04-30 | 0.20x |
| 2026-04-29 | 0.21x |
| 2026-04-28 | 0.21x |
| 2026-04-27 | 0.20x |
| 2026-04-24 | 0.20x |
| 2026-04-23 | 0.21x |
| 2026-04-22 | 0.20x |
| 2026-04-21 | 0.21x |
| 2026-04-20 | 0.21x |
| 2026-04-17 | 0.22x |
| 2026-04-16 | 0.21x |
| 2026-04-15 | 0.21x |
| 2026-04-14 | 0.21x |
| 2026-04-13 | 0.21x |
| 2026-04-10 | 0.21x |
| 2026-04-09 | 0.21x |
| 2026-04-08 | 0.21x |
| 2026-04-07 | 0.21x |
| 2026-04-06 | 0.21x |
| 2026-04-02 | 0.21x |
| 2026-04-01 | 0.21x |
| 2026-03-31 | 0.21x |
| 2026-03-30 | 0.20x |
| 2026-03-27 | 0.21x |
| 2026-03-26 | 0.21x |
| 2026-03-25 | 0.21x |
| 2026-03-24 | 0.21x |
| 2026-03-23 | 0.21x |
| 2026-03-20 | 0.21x |
| 2026-03-19 | 0.22x |
| 2026-03-18 | 0.21x |
| 2026-03-17 | 0.22x |
| 2026-03-16 | 0.23x |
| 2026-03-13 | 0.23x |
| 2026-03-12 | 0.23x |
| 2026-03-11 | 0.23x |
| 2026-03-10 | 0.23x |
| 2026-03-09 | 0.24x |
| 2026-03-06 | 0.23x |
| 2026-03-05 | 0.23x |
| 2026-03-04 | 0.24x |
| 2026-03-03 | 0.24x |
| 2026-03-02 | 0.24x |
| 2026-02-27 | 0.24x |
| 2026-02-26 | 0.24x |
| 2026-02-25 | 0.24x |
| 2026-02-24 | 0.24x |
| 2026-02-23 | 0.24x |
| 2026-02-20 | 0.24x |
| 2026-02-19 | 0.23x |
| 2026-02-18 | 0.23x |
| 2026-02-17 | 0.23x |
| 2026-02-13 | 0.24x |
| 2026-02-12 | 0.23x |
| 2026-02-11 | 0.24x |
| 2026-02-10 | 0.23x |
| 2026-02-09 | 0.24x |
| 2026-02-06 | 0.23x |
| 2026-02-05 | 0.23x |
| 2026-02-04 | 0.22x |
| 2026-02-03 | 0.24x |
| 2026-02-02 | 0.24x |
| 2026-01-30 | 0.24x |
| 2026-01-29 | 0.23x |
| 2026-01-28 | 0.23x |
| 2026-01-27 | 0.23x |
| 2026-01-26 | 0.23x |
| 2026-01-23 | 0.23x |
| 2026-01-22 | 0.23x |
| 2026-01-21 | 0.23x |
| 2026-01-20 | 0.23x |
| 2026-01-16 | 0.23x |
| 2026-01-15 | 0.23x |
| 2026-01-14 | 0.23x |
| 2026-01-13 | 0.23x |
| 2026-01-12 | 0.23x |
| 2026-01-09 | 0.22x |
| 2026-01-08 | 0.22x |
| 2026-01-07 | 0.23x |
| 2026-01-06 | 0.23x |
| 2026-01-05 | 0.23x |
| 2026-01-02 | 0.22x |
| 2025-12-31 | 0.22x |
| 2025-12-30 | 0.23x |
| 2025-12-29 | 0.23x |
| 2025-12-26 | 0.23x |
| 2025-12-24 | 0.22x |
| 2025-12-23 | 0.23x |
| 2025-12-22 | 0.22x |
| 2025-12-19 | 0.23x |
| 2025-12-18 | 0.23x |
| 2025-12-17 | 0.23x |
| 2025-12-16 | 0.23x |
| 2025-12-15 | 0.23x |
| 2025-12-12 | 0.23x |
| 2025-12-11 | 0.23x |
| 2025-12-10 | 0.23x |
| 2025-12-09 | 0.22x |
| 2025-12-08 | 0.22x |
| 2025-12-05 | 0.22x |
| 2025-12-04 | 0.22x |
| 2025-12-03 | 0.22x |
| 2025-12-02 | 0.23x |
| 2025-12-01 | 0.24x |
| 2025-11-28 | 0.24x |
| 2025-11-26 | 0.24x |
| 2025-11-25 | 0.25x |
| 2025-11-24 | 0.25x |
| 2025-11-21 | 0.24x |
| 2025-11-20 | 0.24x |
| 2025-11-19 | 0.24x |
| 2025-11-18 | 0.24x |
| 2025-11-17 | 0.24x |
| 2025-11-14 | 0.24x |
| 2025-11-13 | 0.24x |
| 2025-11-12 | 0.24x |
| 2025-11-11 | 0.24x |
| 2025-11-10 | 0.24x |
| 2025-11-07 | 0.24x |
| 2025-11-06 | 0.24x |
| 2025-11-05 | 0.24x |
| 2025-11-04 | 0.23x |
| 2025-11-03 | 0.23x |
| 2025-10-31 | 0.23x |
| 2025-10-30 | 0.23x |
| 2025-10-29 | 0.22x |
| 2025-10-28 | 0.23x |
| 2025-10-27 | 0.23x |
| 2025-10-24 | 0.22x |
| 2025-10-23 | 0.22x |
| 2025-10-22 | 0.22x |
| 2025-10-21 | 0.22x |
| 2025-10-20 | 0.22x |
| 2025-10-17 | 0.22x |
| 2025-10-16 | 0.22x |
| 2025-10-15 | 0.22x |
| 2025-10-14 | 0.21x |
| 2025-10-13 | 0.21x |
| 2025-10-10 | 0.21x |
| 2025-10-09 | 0.21x |
| 2025-10-08 | 0.21x |
| 2025-10-07 | 0.21x |
| 2025-10-06 | 0.21x |
| 2025-10-03 | 0.21x |
| 2025-10-02 | 0.21x |
| 2025-10-01 | 0.21x |
| 2025-09-30 | 0.21x |
| 2025-09-29 | 0.21x |
| 2025-09-26 | 0.21x |
| 2025-09-25 | 0.20x |
| 2025-09-24 | 0.21x |
| 2025-09-23 | 0.21x |
| 2025-09-22 | 0.20x |
| 2025-09-19 | 0.20x |
| 2025-09-18 | 0.20x |
| 2025-09-17 | 0.20x |
| 2025-09-16 | 0.20x |
| 2025-09-15 | 0.20x |
| 2025-09-12 | 0.21x |
| 2025-09-11 | 0.21x |
| 2025-09-10 | 0.20x |
| 2025-09-09 | 0.20x |
| 2025-09-08 | 0.20x |
| 2025-09-05 | 0.20x |
| 2025-09-04 | 0.20x |
| 2025-09-03 | 0.20x |
| 2025-09-02 | 0.20x |
| 2025-08-29 | 0.20x |
| 2025-08-28 | 0.20x |
| 2025-08-27 | 0.20x |
| 2025-08-26 | 0.20x |
| 2025-08-25 | 0.20x |
| 2025-08-22 | 0.20x |
| 2025-08-21 | 0.21x |
| 2025-08-20 | 0.21x |
| 2025-08-19 | 0.20x |
| 2025-08-18 | 0.20x |
| 2025-08-15 | 0.20x |
| 2025-08-14 | 0.20x |
| 2025-08-13 | 0.20x |
| 2025-08-12 | 0.20x |
| 2025-08-11 | 0.20x |
| 2025-08-08 | 0.19x |
| 2025-08-07 | 0.19x |
| 2025-08-06 | 0.19x |
| 2025-08-05 | 0.20x |
| 2025-08-04 | 0.20x |
| 2025-08-01 | 0.20x |
| 2025-07-31 | 0.20x |
| 2025-07-30 | 0.20x |
| 2025-07-29 | 0.20x |
| 2025-07-28 | 0.20x |
| 2025-07-25 | 0.20x |
| 2025-07-24 | 0.20x |
| 2025-07-23 | 0.20x |
| 2025-07-22 | 0.20x |
| 2025-07-21 | 0.20x |
| 2025-07-18 | 0.20x |
| 2025-07-17 | 0.20x |
| 2025-07-16 | 0.21x |
| 2025-07-15 | 0.20x |
| 2025-07-14 | 0.21x |
| 2025-07-11 | 0.20x |
| 2025-07-10 | 0.21x |
| 2025-07-09 | 0.21x |
| 2025-07-08 | 0.21x |
| 2025-07-07 | 0.21x |
| 2025-07-03 | 0.20x |
| 2025-07-02 | 0.20x |
| 2025-07-01 | 0.20x |
| 2025-06-30 | 0.21x |
| 2025-06-27 | 0.21x |
| 2025-06-26 | 0.21x |
| 2025-06-25 | 0.20x |
| 2025-06-24 | 0.20x |
| 2025-06-23 | 0.20x |
| 2025-06-20 | 0.20x |
| 2025-06-18 | 0.21x |
| 2025-06-17 | 0.20x |
| 2025-06-16 | 0.20x |
| 2025-06-13 | 0.20x |
| 2025-06-12 | 0.20x |
| 2025-06-11 | 0.20x |
| 2025-06-10 | 0.20x |
| 2025-06-09 | 0.20x |
| 2025-06-06 | 0.20x |
| 2025-06-05 | 0.20x |
| 2025-06-04 | 0.20x |
| 2025-06-03 | 0.20x |
| 2025-06-02 | 0.20x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch